Oragenics, Inc. Announces Leadership Transition
12 Fevereiro 2024 - 6:41PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company
focused on developing unique, intranasal nanoparticle
pharmaceuticals for the treatment of neurological disorders, today
announced that, on February 12, 2024, the Company and Kimberly
Murphy, the Company’s Chief Executive Officer, entered into a
mutually agreeable Separation Agreement (the “Separation
Agreement”), pursuant to which Ms. Murphy’s employment with the
Company terminated effective February 12, 2024. Ms. Murphy will,
however, continue to serve the Company as a member of the Company’s
board of directors (the “Board”). The Separation Agreement provides
Ms. Murphy with the benefits under her employment agreement with
the Company for a separation without cause. Ms. Murphy’s
resignation as an officer was not due to any disagreement with the
Company on any matter related to its operations, policies or
practices.
The Board will provide direction to the Company during this
transition in management, with Charlie Pope, the Company’s Chairman
of the Board, serving, on an interim basis, as Executive Chairman,
effective immediately. In addition, effective February 12, 2024,
the Board appointed Michael Redmond, the Company’s President, as
the Company’s Interim Principal Executive Officer.
“We appreciate Ms. Murphy’s strategic leadership on the shift in
the Company’s focus to its recently acquired neurology assets and
look forward to her continued positive impact on and support of the
Company as a director,” said Charles Pope, Executive Chairman of
the Board.
About Oragenics
Oragenics, Inc. is a development-stage company focused on nasal
delivery of pharmaceutical medications in neurology and fighting
infectious diseases including coronaviruses and multidrug-resistant
organisms. Its ONP-002 product candidate is a fully synthetic
neurosteroid being developed to treat Mild Traumatic Brain Injury
(mTBI). Its NT-CoV2-1 product candidate is an intranasal vaccine
candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.
The NT-CoV2-1 program leverages coronavirus spike protein research
licensed from the National Institutes of Health (NIH) and the
National Research Council of Canada (NRC) with a focus on reducing
viral transmission and offering a more patient-friendly intranasal
administration. For more information, please visit
www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including without
limitation statements regarding the ability of the Company to
timely and successfully undertake Phase II clinical trial using its
novel drug - device combination for the treatment of mild Traumatic
Brain Injury. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate
solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to: the
Company’s ability to advance the development of its product
candidates, including the neurology assets, under the timelines and
in accord with the milestones it projects; the Company’s ability to
raise capital and obtain funding, non-dilutive or otherwise, for
the development of its product candidates; the regulatory
application process, research and development stages, and future
clinical data and analysis relating to its product candidates,
including any meetings, decisions by regulatory authorities, such
as the FDA and investigational review boards, whether favorable or
unfavorable; the Company’s ability to obtain, maintain and enforce
necessary patent and other intellectual property protection; the
nature of competition and development relating to concussion
treatments; the Company’s expectations as to the outcome of
preclinical studies and clinical trials and the potential benefits,
activity, effectiveness and safety of its product candidates
including as to administration, transmission, manufacturing,
storage and distribution; and general economic and market
conditions and risks, as well as other uncertainties described in
our filings with the U.S. Securities and Exchange Commission. All
information set forth is as of the date hereof unless otherwise
indicated. You should consider these factors in evaluating the
forward-looking statements included and not place undue reliance on
such statements. We do not assume any obligation to publicly
provide revisions or updates to any forward-looking statements,
whether as a result of new information, future developments or
otherwise, should circumstances change, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240212357218/en/
Oragenics, Inc. Janet Huffman, Chief Financial Officer
813-286-7900 jhuffman@oragenics.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Oragenics (AMEX:OGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024